Isabelle Gaillard - Concepedia

Author

Isabelle Gaillard

Centre National de la Recherche Scientifique ORCID

Also Known As

Calvo-Polanco, Mónica, GAILLARD, Isabelle, Gaillard, I., Gaillard, Isabelle, Gaillard-Sanchez, I., I Gaillard, I Gaillard-Sanchez, I. Gaillard, I. Gaillard-Sanchez, I. Gaillardsanchez

167

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Centre National de la Recherche Scientifique Institut des Sciences des Plantes de Montpellier Institut Agro Montpellier Université de Montpellier Inserm

About

Isabelle Gaillard is an author at Centre National de la Recherche Scientifique specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	21	1.2K
2	Health Sciences	6	6	432
3	Natural Sciences	6	6	335
4	Engineering	3	3	184
5	Social Sciences	1	1	41

Isabelle Gaillard

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy Taoufik El Gnaoui, Jehan Dupuis, Karim Belhadj, Annals of Oncology Hematological MalignancyLymphoid NeoplasiaMedicinePathologyHigh-dose Therapy	2007	158
The Arabidopsis root stele transporter NPF2.3 contributes to nitrate translocation to shoots under salt stress Christelle Taochy, Isabelle Gaillard, Emilie Ipotesi, The Plant Journal	2015	141
Structure of Human Angiotensinogen Gene Isabelle Gaillard, Éric Clauser, Pierre Corvol DNA	1989	133
A grapevine Shaker inward K<sup>+</sup>channel activated by the calcineurin B-like calcium sensor 1âprotein kinase CIPK23 network is expressed in grape berries under drought stress conditions Teresa CuÃ©llar, FranÃ§ois Pascaud, Jean-Luc Verdeil, The Plant Journal	2009	131
Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study Marleen A. E. van der Kaaij, Natacha Heutte, Paul Meijnders, Journal of Clinical Oncology	2011	126
Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial Isabelle Demeestere, Pauline Brice, Fedro A. Peccatori, Journal of Clinical Oncology	2012	121
Eight Cycles of ABVD Versus Four Cycles of BEACOPP<sub>escalated</sub>Plus Four Cycles of BEACOPP<sub>baseline</sub>in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial Patrice Carde, Matthias Karrasch, Catherine Fortpied, Journal of Clinical Oncology	2016	120
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial Nicolas Mounier, Pauline Brice, Serge Bologna, Annals of Oncology Lymphoid NeoplasiaMedicineMalignant Blood DisorderLysa H34Versus Beacopp	2014	107
Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial Natacha Heutte, Hans‐Henning Flechtner, Nicolas Mounier, The Lancet Oncology Quality Of LifeLymphoid Neoplasia10-Year Follow-upHealth SciencesEortc–gela H8	2009	103
AtKC1 is a general modulator of Arabidopsis inward Shaker channel activity Linda Jeanguenin, Carine Alcon, Geoffrey Duby, The Plant Journal Inward SubunitsSignal RecognitionMolecular BiologyGeneral ModulatorCellular Physiology	2011	100

Page 1